EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD11c + B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy

Sahla El Mahdaoui iD, Marie Mathilde Hansen, Marina Rode von Essen iD, Victoria Hyslop Hvalkof, Rikke Holm Hansen iD, Mie Reith Mahler iD, Poul Jennum iD, Finn Sellebjerg iD, Jeppe Romme Christensen iD

Annals of Clinical and Translational Neurology · 2024-04 · 11 (4) · 926-937

DOI: 10.1002/acn3.52009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 08.02.2024. Verfasst von Sahla El Mahdaoui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital - Rigshospitalet, Glostrup, 2600, Denmark. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, B-Lymphocyte Subsets. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Danish Regions through the DanNORMS grant..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

B cells are important in the pathogenesis of multiple sclerosis. It is yet unknown which subsets may be involved, but atypical B cells have been proposed as mediators of autoimmunity. In this study, we investigated differences in B‐cell subsets between controls and patients with untreated and anti‐CD20‐treated multiple sclerosis.

Methods

We recruited 155 participants for an exploratory cohort comprising peripheral blood and cerebrospinal fluid, and a validation cohort comprising peripheral blood. Flow cytometry was used to characterize B‐cell phenotypes and effector functions of CD11c + atypical B cells.

Results

There were no differences in circulating B cells between controls and untreated multiple sclerosis. As expected, anti‐CD20‐treated patients had a markedly lower B‐cell count. Of B cells remaining after treatment, we observed higher proportions of CD11c + B cells and plasmablasts. CD11c + B cells were expanded in cerebrospinal fluid compared to peripheral blood in controls and untreated multiple sclerosis. Surprisingly, the proportion of CD11c + cerebrospinal fluid B cells was higher in controls and after anti‐CD20 therapy than in untreated multiple sclerosis. Apart from the presence of plasmablasts, the cerebrospinal fluid B‐cell composition after anti‐CD20 therapy resembled that of controls. CD11c + B cells demonstrated a high potential for both proinflammatory and regulatory cytokine production.

Interpretation

The study demonstrates that CD11c + B cells and plasmablasts are less efficiently depleted by anti‐CD20 therapy, and that CD11c + B cells comprise a phenotypically and functionally distinct, albeit heterogenous, B‐cell subset with the capacity of exerting both proinflammatory and regulatory functions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingMultiple SclerosisB-Lymphocyte SubsetsHumansB-LymphocytesPlasma Cells

Autor:innen und Institutionen

  • Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital - Rigshospitalet, Glostrup, 2600, Denmark.
  • Department of Neurology, Danish Center for Sleep Medicine, Copenhagen University Hospital - Rigshospitalet, Glostrup, 2600, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, 2200, Denmark.

ORCID-Profile: Sahla El Mahdaoui, Marina Rode von Essen, Rikke Holm Hansen, Mie Reith Mahler, Poul Jennum, Finn Sellebjerg, Jeppe Romme Christensen

Förderung

  • The Danish Regions through the DanNORMS grant.

Zitieren

APA

El Mahdaoui, S., Hansen, M. M., von Essen, M. R., Hvalkof, V. H., Holm Hansen, R., Mahler, M. R., Jennum, P., Sellebjerg, F., & Romme Christensen, J. (2024). CD11c + B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy. Annals of Clinical and Translational Neurology, 11(4), 926-937. https://doi.org/10.1002/acn3.52009

Vancouver

El Mahdaoui S, Hansen MM, von Essen MR, Hvalkof VH, Holm Hansen R, Mahler MR, et al. CD11c + B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy. Annals of Clinical and Translational Neurology. 2024;11(4):926-937. doi:10.1002/acn3.52009

BibTeX
@article{ElMahdaoui2024,
  author = {El Mahdaoui, Sahla and Hansen, Marie Mathilde and von Essen, Marina Rode and Hvalkof, Victoria Hyslop and Holm Hansen, Rikke and Mahler, Mie Reith and Jennum, Poul and Sellebjerg, Finn and Romme Christensen, Jeppe},
  title = {CD11c + B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  volume = {11},
  number = {4},
  pages = {926--937},
  doi = {10.1002/acn3.52009}
}
Kostenlos starten →